Barrera Aveleida Giovanna Berenice

Dr. Barrera Aveleida Giovanna Berenice

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
DFDavid Figueroa
David Figueroa
DCDaniela Nahomi Calderón-Sandate
Daniela Nahomi Calderón-Sandate
JCJonathan Hernández Castillo
Jonathan Hernández Castillo
MHManuel Josafat Huerta-Garza
Manuel Josafat Huerta-Garza
XRXimena Hernández Rodríguez
Ximena Hernández Rodríguez
Luis Adrián De Jesús GonzálezLuis Adrián De Jesús González
Luis Adrián De Jesús González
RNA viruses remain a significant public health concern due to their rapid evolution, genetic variability, and capacity to trigger recurrent epidemics and pandemics. Over the last decade, natural products have gained attention as a valuable source of antiviral candidates, offering structural diversity, accessibility, and favorable safety profiles. This review highlights key replication mechanisms of RNA viruses and their associated therapeutic targets, including RNA-dependent RNA polymerase, viral proteases, and structural proteins mediating entry and maturation. We summarize recent advances in the identification of bioactive compounds such as flavonoids, alkaloids, terpenes, lectins, and polysaccharides that exhibit inhibitory activity against clinically relevant pathogens, including the Influenza A virus (IAV), human immunodeficiency viruses (HIV), dengue virus (DENV), Zika virus (ZIKV), and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Special emphasis is placed on the integration of in silico screening, in vitro validation, and nanotechnology-based delivery systems that address challenges of stability, bioavailability, and specificity. Furthermore, the growing role of artificial intelligence, drug repurposing strategies, and curated antiviral databases is discussed as a means to accelerate therapeutic discovery. Despite persistent limitations in clinical translation and standardization, natural products represent a promising and sustainable platform for the development of next-generation antivirals against RNA viruses.

30 April 2026 in Microbiological Research
Verified
Journal Article
Closed access
LOLuisa Fernanda Ontiveros-Zúñiga
Luisa Fernanda Ontiveros-Zúñiga
SSSharon Itzel Sosa-Mondragon
Sharon Itzel Sosa-Mondragon
JOJuan Fidel Osuna-Ramos
Juan Fidel Osuna-Ramos
RLRandy Seir Llanas-Vázquez
Randy Seir Llanas-Vázquez
DFDavid Figueroa
David Figueroa
Luis Adrián De Jesús GonzálezLuis Adrián De Jesús González
Luis Adrián De Jesús González

Verified
Journal Article
Open access
PDF file
ARAlbany Resendiz-Mora
Albany Resendiz-Mora
BBBarrera Aveleida Giovanna Berenice
Barrera Aveleida Giovanna Berenice
ASAnahi Sotelo-Rodriguez
Anahi Sotelo-Rodriguez
EGEdgar Iván Galarce-Sosa
Edgar Iván Galarce-Sosa
CNChristian Irene Nevarez-Lechuga
Christian Irene Nevarez-Lechuga
CWCarlos Wong-Baeza
Carlos Wong-Baeza
Chagas disease is caused by Trypanosoma cruzi and represents a major public health problem, which is endemic in Latin America and emerging in the rest of the world. The two drugs that are currently available for its treatment, Benznidazole and Nifurtimox, are partially effective in the chronic phase of the disease. In this study, we designed and synthesized the benzyl ester of N-isopropyl oxamic acid (B-NIPOx), which is a non-polar molecule that crosses cell membranes. B-NIPOx is cleaved inside the parasite by carboxylesterases, releasing benzyl alcohol (a molecule with antimicrobial activity), and NIPOx, which is an inhibitor of α-hydroxy acid dehydrogenase isozyme II (HADH-II), a key enzyme in T. cruzi metabolism. We evaluated B-NIPOx cytotoxicity, its toxicity in mice, and its inhibitory activity on purified HADH-II and on T. cruzi homogenates. We then evaluated the trypanocidal activity of B-NIPOx in vitro and in vivo and its effect in the intestine of T. cruzi-infected mice. We found that B-NIPOx had higher trypanocidal activity on epimastigotes and trypomastigotes than Benznidazole and Nifurtimox, that it was more effective to reduce blood parasitemia and amastigote nests in infected mice, and that, in contrast to the reference drugs, it prevented the development of Chagasic enteropathy.

23 June 2022 in Membranes
Verified
Journal Article
Open access
PDF file
CLCarla Landa-Saldívar
Carla Landa-Saldívar
ARAlbany Resendiz-Mora
Albany Resendiz-Mora
SBSandra Sánchez Barbosa
Sandra Sánchez Barbosa
ASAnahi Sotelo-Rodriguez
Anahi Sotelo-Rodriguez
BBBarrera Aveleida Giovanna Berenice
Barrera Aveleida Giovanna Berenice
CWCarlos Wong-Baeza
Carlos Wong-Baeza
Liposomes are artificial models of cellular membranes that are used as delivery systems for genes, drugs and protein antigens. We have previously used them to study the antigenic properties of their phospholipids. Here, we used them to induce the production of IgG anti-non-bilayer phospholipid arrangements (NPAs) antibodies in mice; these antibodies cause cell lysis and trigger a lupus-like disease in mice. We studied the mechanisms that lead to the production of these antibodies, and provide evidence that NK1.1+, CD4+ T cells respond to NPA-bearing liposomes and deliver the help required for specific B cell activation and antibody class-switching to IgG. We found increased numbers of IL-4-producing NK1.1+, CD4+ T cells in the secondary lymphoid organs of mice administered with NPAs, and these cells also expressed CD40L, which is required for B cell activation. Additionally, we isolated and purified NK1.1+, CD4+ T cells from spleens and determined that they over-expressed 40 genes, which are key players in inflammatory processes and B cell stimulation and have TRAF6 and UNC39B1 as key nodes in their network. These results show that liposomes are membrane models that can be used to analyze the immunogenicity of lipids.

Verified
Journal Article
Open access
PDF file
EGEdgar Iván Galarce-Sosa
Edgar Iván Galarce-Sosa
ARAlbany Resendiz-Mora
Albany Resendiz-Mora
RMRodrigo Ramos Monteagudo
Rodrigo Ramos Monteagudo
BBBarrera Aveleida Giovanna Berenice
Barrera Aveleida Giovanna Berenice
JRJosé Rundquist-Sánchez
José Rundquist-Sánchez
IBIsabel Baeza
Isabel Baeza
Anti-lipid autoantibodies are produced in systemic lupus erythematosus (SLE). These antibodies are associated with clinical manifestations of the disease, such as thrombosis, cardiovascular events, and neurological disorders. However, the cellular and molecular mechanisms that lead to the production of these antibodies are not well known. We developed a mouse model of lupus by administering liposomes bearing non-bilayer phospholipid arrangements (NPA) stabilized by chlorpromazine. These mice produce anti-NPA antibodies that trigger a lupus-like disease. In previous studies, we demonstrated that these antibodies are primarily produced by germinal centers and that NK1.1+ CD4+ T cells provide help to B cells, enabling them to produce these IgG antibodies. However, additional immune cells may contribute to the production of these antibodies. Therefore, in this work, we analyzed the in vivo responses of γδ T cells and macrophages in this mouse model. We found that γδ T cells from mice that produce anti-NPA antibodies produce IFNγ and IL-17, which can contribute to B cell class switching and production of anti-NPA IgG antibodies via germinal centers. Additionally, we found that macrophages are polarized into a proinflammatory M1 phenotype and produce IL-6 that can exacerbate inflammation and potentially lead to autoimmunity.